title: Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease.
abstract: Weight changes are common in aging and Alzheimer's disease (AD) and postmortem findings suggest a relation between lower body mass index (BMI) and increased AD brain pathology. In the current multicenter study, we tested whether lower BMI is associated with higher core AD brain pathology as assessed by cerebrospinal fluid (CSF)-based biological markers of AD in 751 living subjects: 308 patients with AD, 296 subjects with amnestic mild cognitive impairment (MCI), and 147 elderly healthy controls (HC). Based upon a priori cutoff values on CSF concentration of total tau and beta-amyloid (Aβ(1-42)), subjects were binarized into a group with abnormal CSF biomarker signature (CSF+) and those without (CSF-). Results showed that BMI was significantly lower in the CSF+ when compared with the CSF- group (F = 27.7, df = 746, p < 0.001). There was no interaction between CSF signature and diagnosis or apolipoprotein E (ApoE) genotype. In conclusion, lower BMI is indicative of AD pathology as assessed with CSF-based biomarkers in demented and nondemented elderly subjects.
authors.affiliation: University of California, VA Medical Center, Center for Neuroimaging of Neurodegenerative Diseases , San Francisco, San Francisco, CA 94121, USA. michael.ewers@va.gov
authors.forename: Michael
authors.initials: M
authors.lastname: Ewers
authors.forename: Susanne
authors.initials: S
authors.lastname: Schmitz
authors.forename: Oskar
authors.initials: O
authors.lastname: Hansson
authors.forename: Cathal
authors.initials: C
authors.lastname: Walsh
authors.forename: Annette
authors.initials: A
authors.lastname: Fitzpatrick
authors.forename: David
authors.initials: D
authors.lastname: Bennett
authors.forename: Lennart
authors.initials: L
authors.lastname: Minthon
authors.forename: John Q
authors.initials: JQ
authors.lastname: Trojanowski
authors.forename: Leslie M
authors.initials: LM
authors.lastname: Shaw
authors.forename: Yetunde O
authors.initials: YO
authors.lastname: Faluyi
authors.forename: Bruno
authors.initials: B
authors.lastname: Vellas
authors.forename: Bruno
authors.initials: B
authors.lastname: Dubois
authors.forename: Kaj
authors.initials: K
authors.lastname: Blennow
authors.forename: Katharina
authors.initials: K
authors.lastname: Buerger
authors.forename: Stefan J
authors.initials: SJ
authors.lastname: Teipel
authors.forename: Michael
authors.initials: M
authors.lastname: Weiner
authors.forename: Harald
authors.initials: H
authors.lastname: Hampel
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000453:epidemiology*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000134:cerebrospinal fluid; D015992:Body Mass Index; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D003072:Cognition Disorders / Q000134:cerebrospinal fluid* / Q000453:epidemiology* / Q000473:pathology; D015897:Comorbidity; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000134:cerebrospinal fluid; D015995:Prevalence; D011379:Prognosis; D013223:Statistics as Topic; D014481:United States / Q000453:epidemiology; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins